Subtype
Ependymal Tumor
CI-CAN-00002591Explore in graph →
Non-malignant42 active trials20 evidence items
Loading cancer entity…
Subtype
CI-CAN-00002591Explore in graph →
Clinical trials
151 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01445288 | Exploratory Study of Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors | completed | — | 76 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07031765 | Peds CHAMP1ON - Hematopoietic Stem Cell And Monoclonal Antibody PD-1 Blockade for RecurreNt Pediatric High-Grade Glioma(Peds CHAMP1ON) | active not recruiting | Phase 1 | 12 | University of FloridaOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT03210714 | Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) | active not recruiting | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 2 | Sep 22, 2026 | clinicaltrials |
Data updated yesterdaySource updated Sep 28, 2026source: clinicaltrials
| NCT03251989 | Rare CNS Tumors Outcomes &Risk | completed | — | 326 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT03698994 | Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) | active not recruiting | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 2 | Sep 21, 2026 | clinicaltrials |
| NCT06804655 | Pharmacoscopy for Patients With Refractory Primary Brain Tumors(EViDENCE-BT) | recruiting | Phase 2 | 40 | University of ZurichOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06639607 | PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma(PRiME II) | suspended | Phase 1 / Phase 2 | 68 | Washington University School of MedicineOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07061626 | Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in Pediatric Recurrent, Refractory or Progressive Ependymoma and High-Grade Glioma | recruiting | Phase 1 | 56 | CerenomeINDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07390539 | B7-H3.CD28Z.CART in CNS Neoplasms | recruiting | Phase 1 | 70 | Robbie MajznerOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT04374305 | Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)(INTUITT-NF2) | recruiting | Phase 2 | 109 | Scott R. Plotkin, MD, PhDOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05857969 | Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling | recruiting | Phase 1 | 65 | Florida International UniversityOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT03173950 | Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers | terminated | Phase 2 | 136 | National Cancer Institute (NCI)NIH | 1 | Aug 18, 2026 | clinicaltrials |
| NCT03389802 | Phase I Study of APX005M in Pediatric Central Nervous System Tumors | completed | Phase 1 | 32 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Aug 13, 2026 | clinicaltrials |
| NCT06161519 | PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications | recruiting | Phase 1 / Phase 2 | 146 | National Cancer Institute (NCI)NIH | 1 | Aug 12, 2026 | clinicaltrials |
| NCT05057702 | Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma(PNOC027) | recruiting | N/A | 74 | University of California, San FranciscoOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT03900689 | Social Determinants of Health in Glioblastoma Population | completed | — | 100 | Wake Forest University Health SciencesOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT04099797 | C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B) | recruiting | Phase 1 | 56 | Baylor College of MedicineOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT04320888 | Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial | active not recruiting | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 3 | Aug 3, 2026 | clinicaltrials |
| NCT04743661 | 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma | active not recruiting | Phase 2 | 62 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Jul 28, 2026 | clinicaltrials |
| NCT03155620 | Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) | active not recruiting | Phase 2 | 1,377 | National Cancer Institute (NCI)NIH | 4 | Jul 24, 2026 | clinicaltrials |
| NCT07703605 | AI-Assisted MRI Molecular Subtyping in Pediatric Brain Tumors | not yet recruiting | — | 1,400 | Huashan HospitalOTHER | 0 | Jul 23, 2026 | clinicaltrials |
| NCT02359565 | Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma | active not recruiting | Phase 1 | 71 | National Cancer Institute (NCI)NIH | 2 | Jul 20, 2026 | clinicaltrials |
| NCT05278208 | Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors | recruiting | Phase 1 / Phase 2 | 65 | Nationwide Children's HospitalOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07713745 | Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2)(PRIME-NF2) | not yet recruiting | Phase 2 | 200 | Beijing Tiantan HospitalOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07707947 | Selumetinib for NF2-Related Schwannomatosis(ASSIST) | not yet recruiting | Phase 2 | 20 | Beijing Tiantan HospitalOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT04284774 | Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial | active not recruiting | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 2 | Jul 15, 2026 | clinicaltrials |
| NCT03213652 | Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) | active not recruiting | Phase 2 | 13 | National Cancer Institute (NCI)NIH | 4 | Jul 10, 2026 | clinicaltrials |
| NCT05835687 | Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors | active not recruiting | Phase 1 | 29 | St. Jude Children's Research HospitalOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT04195555 | Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) | active not recruiting | Phase 2 | 3 | National Cancer Institute (NCI)NIH | 3 | Jul 1, 2026 | clinicaltrials |
| NCT03194906 | Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors | completed | Phase 2 | 41 | St. Jude Children's Research HospitalOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT00840047 | Methionine PET/CT Studies In Patients With Cancer | active not recruiting | Phase 2 | 503 | St. Jude Children's Research HospitalOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT03213704 | Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) | active not recruiting | Phase 2 | 9 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT06193759 | Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)(IMPACT) | recruiting | Phase 1 | 12 | Children's National Research InstituteOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT04732065 | ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors(PNOC023) | recruiting | Phase 1 | 208 | Sabine Mueller, MD, PhDOTHER | 3 | Jun 11, 2026 | clinicaltrials |
| NCT06607692 | Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).(LUPARPED) | recruiting | Phase 1 / Phase 2 | 25 | Fundación de investigación HMOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT03033992 | Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With DIPG | active not recruiting | N/A | 80 | Children's Oncology GroupNETWORK | 1 | Jun 2, 2026 | clinicaltrials |
| NCT04903080 | HER2-specific Chimeric Antigen Receptor (CAR) T Cells for Children With Ependymoma | active not recruiting | Phase 1 | 50 | Children's Oncology GroupNETWORK | 2 | Jun 2, 2026 | clinicaltrials |
| NCT04978727 | A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma | active not recruiting | Phase 1 | 35 | Children's Oncology GroupNETWORK | 2 | Jun 2, 2026 | clinicaltrials |
| NCT07424092 | Intratumoral DNX-2401 for High Grade Pediatric Brain Tumors(PED-DNX2401) | recruiting | Phase 2 | 39 | Clinica Universidad de Navarra, Universidad de NavarraOTHER | 2 | May 27, 2026 | clinicaltrials |
| NCT03750513 | LET Optimized IMPT in Treating Pediatric Patients With Ependymoma | recruiting | Phase 1 | 48 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT07589361 | Safety and Efficacy of Vertebral Body-Sparing Craniospinal Irradiation With Proton Therapy in Pediatric Tumors(VBS-CSI-PT-PED) | not yet recruiting | — | 38 | Ruijin HospitalOTHER | 0 | May 15, 2026 | clinicaltrials |
| NCT01096368 | Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma | completed | Phase 3 | 479 | Children's Oncology GroupNETWORK | 4 | Apr 30, 2026 | clinicaltrials |
| NCT05934630 | Testing Cerebrospinal Fluid for Cell-free Tumor DNA in Children, Adolescents, and Young Adults With Brain Tumors | terminated | — | 57 | Pediatric Brain Tumor ConsortiumNETWORK | 2 | Apr 23, 2026 | clinicaltrials |
| NCT03213678 | Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 2 | Apr 21, 2026 | clinicaltrials |
| NCT03213665 | Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 2 | Apr 13, 2026 | clinicaltrials |
| NCT04185038 | Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors | recruiting | Phase 1 | 90 | Seattle Children's HospitalOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT03526250 | Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 2 | Apr 3, 2026 | clinicaltrials |
| NCT04661384 | Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma | active not recruiting | Phase 1 | 10 | City of Hope Medical CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT03152318 | A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2(rQNestin) | active not recruiting | Phase 1 | 62 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT02125786 | A Trial of Surgery and Fractionated Re-Irradiation for Recurrent Ependymoma | active not recruiting | Phase 2 | 68 | St. Jude Children's Research HospitalOTHER | 1 | Feb 24, 2026 | clinicaltrials |